|UPDATE: Information below is retained for historical purposes. Artifacts of the challenge are available through the following digital object identifier: http://dx.doi.org/10.7937/K9/TCIA.2015.zF0vlOPv.|
The National Cancer Institute’s (NCI's) Cancer Imaging Program in collaboration with the International Society for Biomedical Imaging (ISBI) has launched a grand challenge involving prostate gland magnetic resonance imaging (MRI) data. The challenge will take place at the ISBI Symposium, April 7-11, 2013 in San Francisco, CA.
NOTE: Information below is retained for historical purposes. Artifacts of the challenge are available through the following digital object identifier: http://dx.doi.org/10.7937/K9/TCIA.2015.zF0vlOPv.
Prostate cancer is the second most common cause of cancer deaths in males and will afflict 1 in 6 men. Many diagnostic prostate biopsies fail to detect occult cancers because of the difficulty in properly determining the prostate’s anatomy. Approximately 20% of ultrasound image guided prostate biopsies return negative results despite rising levels of prostate-specific antigen (PSA) markers in the blood and the presence of cancer somewhere in the 30+ cc gland. These failures have been attributed by some to the hesitation to sample one of the two major parts of the glands— namely the predilection toward the more easily reached peripheral zone (PZ) over the less accessible central gland (CG). This year’s ISBI challenge contestants outlined these two non-overlapping adjacent regions of the gland (see image).